David Cipolla

Biography

Dr. Cipolla holds a chemical engineering degree from MIT (S.B.) and UC Davis (M.S.) and a pharmacy degree from the University of Sydney (Ph.D.). Dr. Cipolla currently leads the preclinical research, pharmaceutical sciences and intellectual property efforts at Aradigm Corp and has served in various scientific and technical capacities at Aradigm since 1996. Prior to joining Aradigm, Dr. Cipolla worked at Genentech, Inc. (1988-1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis. Dr. Cipolla has contributed in a number of roles on pharmaceutical consortia (including chair of IPAC-RS), academic societies (ISAM board member) and on the editorial board of multiple scientific journals

Research Interest

Biotechnology, Clinical Research, Clinical Trials